SPECIALTY TOPICS

CURRENTLY VIEWING
Immunotherapy in Melanoma

Immunotherapy in Melanoma

AACR 2018: Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma

Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial.
Read More >>

FDA Approves 4-Week Nivolumab Dosing Schedule

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

Weber Shares Insight on Future of Immunotherapy in Melanoma

Ipilimumab Approved in Europe for Pediatric Melanoma

Adjuvant Pembrolizumab Improves RFS in Melanoma

View More Stories >>

View Conference Coverage

2018 AACR Annual Meeting

2018 European Lung Cancer Congress

2018 SGO Annual Meeting

2018 State of the Science Summit on Gastrointestinal Malignancies

2018 State of the Science Summit on Prostate Cancer

Dr. Whitman on the Role of Pembrolizumab in Melanoma

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Advances in Treating Melanoma: Closing Thoughts

COMBI-AD: Dual-Targeted Therapy for Stage 3 Melanoma

Alternative Approaches to Treating Melanoma

Emerging Agents and Combinations for Advanced Melanoma

Considering Chemotherapy's Value in Melanoma

Melanoma: Mechanisms of Resistance to Therapy

Targeting NRAS Mutations in Metastatic Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Less Common Side Effects With Immunotherapy in Melanoma

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

Immunotherapy-Related Pulmonary Toxicities in Melanoma

Melanoma: Management of Dermatologic Toxicities

Overall Toxicities With Immunotherapy in Melanoma

Monotherapy Versus Combination Therapy Approaches in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Metastatic Melanoma: The New Millennium

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now